New Cancer Data Shine Spotlight On The Secret Committees That Make Medicine’s Toughest Decisions – Forbes

Not sure how the system works in other countries but a fascinating article by Forbes on the Data Safety Monitoring Boards that decide when clinical trials stop and when they can continue.

Not easy decisions, balancing the wish to get new drugs out earlier (e.g., no longer ethical to give patients a placebo) against safety and outcome concerns (see earlier post on this aspect here). And the role of drug companies in possibly influencing the DSMBs is also of concern (likely tempered by litigation and other worries if they get it wrong).

New Cancer Data Shine Spotlight On The Secret Committees That Make Medicine’s Toughest Decisions – Forbes.

Advertisements

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s